Amended Statement of Beneficial Ownership (sc 13d/a)
February 21 2018 - 2:38PM
Edgar (US Regulatory)
|
|
|
OMB
APPROVAL
|
|
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
OMB
Number: 3235-0145
Expires: February
28, 2009
Estimated
average burden
hours
per response ......... 14.5
|
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
(Amendment No. 3)*
VASCULAR
BIOGENICS LTD.
(Name
of Issuer)
ORDINARY
SHARES, NIS 0.01 PAR VALUE PER SHARE
(Title
of Class of Securities)
M
96883109
(CUSIP
Number)
Thai
Lee, 98 San Jacinto Boulevard, Austin, Texas 78701 (732) 868-0800
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
February
2, 2018
(Date
of Event which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
§240.13d-7 for other parties to whom copies are to be sent.
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section
18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13D
CUSIP No.
|
M 96883109
|
|
|
Page
|
2
|
of
|
8
|
Pages
|
|
|
1
|
NAMES OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Thai Lee Family Trust
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a)
☐
(b)
☐
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (See Instructions)
00
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
N/A
|
☐
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
|
7
|
SOLE VOTING POWER
0
|
8
|
SHARED VOTING POWER
2,192,007
|
9
|
SOLE DISPOSITIVE POWER
0
|
10
|
SHARED DISPOSITIVE POWER
2,192,007
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,192,007.
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES (See Instructions)
|
☐
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.1%
|
14
|
TYPE OF REPORTING PERSON (See Instructions)
00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SCHEDULE 13D
CUSIP
No.
|
M
96883109
|
|
|
Page
|
3
|
of
|
8
|
Pages
|
|
|
1
|
NAMES
OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Thai Lee
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(c)
☐
(d)
☐
|
3
|
SEC
USE ONLY
|
4
|
SOURCE
OF FUNDS (See Instructions)
00,
PF
|
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
N/A
|
☐
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
New
Jersey
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
|
7
|
SOLE
VOTING POWER
3,255,407(1)
|
8
|
SHARED
VOTING POWER
2,192,007
|
9
|
SOLE
DISPOSITIVE POWER
3,255,804(1)
|
10
|
SHARED
DISPOSITIVE POWER
2,192,007
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,447,811(1)
|
12
|
CHECK
IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
☐
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
20%
|
14
|
TYPE
OF REPORTING PERSON (See Instructions)
IN
|
(1)
|
|
Includes
259,207 shares held in UMTA accounts for the Reporting Person’s children. The Reporting Person disclaims
beneficial ownership of these shares.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 1.
|
Security and Issuer Identity and Background
|
This Schedule 13D (the
“Schedule 13D”) relates to the Ordinary Shares, NIS 0.01 par value (“Ordinary Shares”), of Vascular Biogenics
Ltd. (the “Issuer”).
The principal executive
offices of the Issuer are located at 6 Jonathan Netanyahu Street, Or Yehuda Israel 60376.
|
Item 2.
|
Identity and Background
|
|
(a)
|
This Schedule 13D is filed on behalf of Thai Lee Family Trust (the “Trust”) and Thai
Lee (“Lee”) (and, collectively with the Trust, the “Reporting Persons”).
|
|
(b)
|
The principal business address of each of the Reporting Persons is 98 San Jacinto Boulevard, Austin,
Texas 78701.
|
|
(c)
|
The Trust is a trust formed under the laws of the State of New Jersey which maintains an address
at 290 Davidson Avenue, Somerset, New Jersey 08873. Lee is the sole trustee of the Trust.
|
|
(d)
|
During the past five years, neither of the Reporting Persons has been convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors).
|
|
(e)
|
During the past five years, neither of the Reporting Persons has been a party to a civil proceeding
of a judicial or administrative body of competent jurisdiction, and as a result of which was subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding
any violations with respect to such laws.
|
|
(f)
|
The Trust is organized under the laws of the State of New Jersey. Lee is a United States citizen.
|
|
Item 3.
|
Source and Amount of Funds or Other Consideration
|
The Reporting Persons
are filing this Amendment No. 3 to report the acquisition by Lee through open market purchases of an aggregate of Ordinary Shares
from February 2, 2018 through February 9, 2018. These purchases were funded by the personal funds of Lee.
|
Item 4.
|
Purposes of Transactions
|
On January 31, 2014,
Lee, the Trust, Keffi VI and other parties entered into a Loan and Forbearance Agreement pursuant to which Keffi VI and another
debtor issued (i) a promissory note to the Trust in connection with a loan made pursuant to such Loan and Forbearance Agreement
and (ii) an amended and restated promissory note to Lee which replaced certain promissory notes previously issued to Lee. The Trust
and Lee loaned additional amounts to Keffi VI and another debtor in August 2014 pursuant to a demand promissory note.
The obligations of
Keffi VI and the other debtor under the notes issued to the Trust and Lee were secured by, among other things, a pledge of the
Ordinary Shares of the Issuer owned by Keffi VI. In connection with such pledge, Keffi VI, Lee, the Trust and JPMorgan Chase Bank
N.A. (the “Intermediary”) entered into a Securities Account Control Agreement dated May 4, 2015 which provides that
at such time as Lee and the Trust send a Notice of Exclusive Control to the Intermediary, the Intermediary may thereafter honor
solely the orders of Lee and the Trust concerning the account in which the pledged Ordinary Shares are held. On January 19, 2016,
following a default under the Loans, Lee and the Trust delivered a Notice of Exclusive Control to the Intermediary which gave Lee
and the Trust the right to direct the vote and disposition of the Ordinary Shares of the Issuer held in the account.
On September 15, 2016,
the Trust exercised its rights as a secured creditor and acquired legal title to the Shares.
Between March 23, 2017
and August 23, 2017, the Reporting Persons acquired additional shares as reported in Amendment No. 2 to this Schedule 13D.
Between February 2,
2018 and February 9, 2018, Lee acquired additional shares as set forth in Item 5 below.
The Reporting Persons
have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional
securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a
merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount
of assets of the Issuer or any of its subsidiaries; (d) any change in the present Board of Directors or management of the Issuer,
including any plans or proposals to change the number of or term of directors or to fill any existing vacancies on the board; (e)
any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer’s
business or corporate structure; (g) changes in the Issuer’s charter, by-laws or instruments corresponding thereto or other
actions which may impede the acquisition of control of the Issuer by any person; (h) causing a class of securities of the Issuer
to be delisted from a national securities exchange or cease to be authorized to be quoted in an inter-dealer quotation system of
a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination
of registration pursuant to Section 12(g) (4) of the Act, as amended or (j) any action similar to those enumerated above; however,
the Reporting Persons at any time and from time to time, may acquire additional securities or dispose of any or all of the securities
owned by them depending upon an ongoing evaluation of the investment in the securities, prevailing market conditions and other
investment opportunities.
|
Item 5.
|
Interest in Securities of the Issuer
|
(a) The
aggregate number of Ordinary Shares beneficially owned by the Reporting Persons as of the date of this Schedule 13D is 5,447,811
shares, or approximately 20% of the class of securities identified in Item 1 based on 27,224,566 Ordinary Shares outstanding as
of September 30, 2017, as reported in the Issuer’s Form 424B5 filed by the Issuer with the Securities and Exchange Commission
on November 20, 2017.
(b) The
number of Ordinary Shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the
vote, sole power to dispose or direct the disposition, or shared power to dispose or direct the disposition, or shared power to
dispose or direct the disposition for the Reporting Person is set forth in Items 7 to 10 of pages 2-3 of this Schedule 13D and
such information is incorporated herein by reference.
(c) The
following sets forth the purchases of Issuer’s Ordinary Shares made by the Reporting Persons since February 2, 2018:
Date
|
|
No. of Shares
(1)
|
|
Purchase Price Per Share
|
|
|
|
|
|
2-2-18
|
|
18,600
|
|
|
$
|
6.40
|
|
2-2-18
|
|
1,400
|
|
|
$
|
6.39
|
|
2-2-18
|
|
500
|
|
|
$
|
6.35
|
|
2-5-18
|
|
19,500
|
|
|
$
|
6.35
|
|
2-5-18
|
|
20,000
|
|
|
$
|
6.30
|
|
2-5-18
|
|
20,000
|
|
|
$
|
6.25
|
|
2-6-18
|
|
8,014
|
|
|
$
|
6.05
|
|
2-6-18
|
|
66
|
|
|
$
|
6.03
|
|
2-7-18
|
|
11,820
|
|
|
$
|
6.05
|
|
2-8-18
|
|
20,000
|
|
|
$
|
6.35
|
|
2-9-18
|
|
20,000
|
|
|
$
|
6.25
|
|
2-9-18
|
|
11,338
|
|
|
$
|
6.10
|
|
2-16-18
|
|
397
|
|
|
$
|
6.10
|
|
|
(1)
|
All shares purchased by Thai Lee.
|
(d) Not
applicable.
(e) Not
applicable.
|
Item 6.
|
Contracts, Arrangements, Understandings or Relationships With Respect to the Securities of the
Issuer
|
No contracts, arrangements,
understandings or relationships (legal or otherwise) exist among the persons named in Item 2 or between any of the Reporting Persons
and any other person with respect to any securities of the Issuer, including but not limited to transfer or voting of any such
securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of
profits or loss, or the giving or withholding of proxies, except the Loan and Forbearance Agreement, Security Agreement and Securities
Account Control Agreement described in Item 4 above.
Item 7.
|
Material to be Filed as Exhibits
|
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 21, 2018
|
Thai Lee Family Trust
|
|
|
|
|
By:
|
/s/ Thai Lee
|
|
Name:
|
Thai Lee
|
|
Title:
|
Trustee
|
|
|
|
|
|
/s/ Thai Lee
|
|
|
Thai Lee
|
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024